Skip to main content
OpenTrials

Clinical trial condition

Relapsing Multiple Sclerosis

Explore clinical trials studying Relapsing Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

68 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Relapsing Multiple Sclerosis trial results

Completed

A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

NCT04626921

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Cranial Nerve Diseases, +9 more
Locations
  • Sydney Brain Mind Centre Camperdown, New South Wales, Australia
  • John Hunter Hospital New Lambton Heights, New South Wales, Australia
  • Princess Alexandra Hospital Woolloongabba, Queensland, Australia
  • Menzies Institute for Medical Research Hobart, TAZ, Australia
View Trial Details
Completed

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis

NCT03856619

Conditions
Relapsing Multiple Sclerosis
Locations
  • Investigational Site Number :024 Ahmedabad, India
  • Investigational Site Number :017 Bengaluru, India
  • Investigational Site Number :001 Chandigarh, India
  • Investigational Site Number :023 Coimbatore, India
View all 14 locations
View Trial Details
Completed

A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04847596

Conditions
COVID-19, Coronaviridae Infections, Coronavirus Infections, +10 more
Locations
  • Novartis Investigative Site Phoenix, Arizona, United States
  • Novartis Investigative Site Owosso, Michigan, United States
  • Novartis Investigative Site St Louis, Missouri, United States
  • Novartis Investigative Site Plainview, New York, United States
View Trial Details
Completed

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

NCT03249714

Conditions
Relapsing Multiple Sclerosis
Locations
  • Novartis Investigative Site Tōon, Ehime, Japan
  • Novartis Investigative Site Fukuoka, Japan
  • Novartis Investigative Site Sapporo, Hokkaido, Japan
  • Novartis Investigative Site Morioka, Iwate, Japan
View all 14 locations
View Trial Details
Completed

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

NCT03257358

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Novartis Investigative Site Birmingham, Alabama, United States
  • Novartis Investigative Site Cullman, Alabama, United States
  • Novartis Investigative Site Tucson, Arizona, United States
  • Novartis Investigative Site Berkeley, California, United States
View all 66 locations
View Trial Details
Completed

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

NCT02792218

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +9 more
Locations
  • Novartis Investigative Site Phoenix, Arizona, United States
  • Novartis Investigative Site Berkeley, California, United States
  • Novartis Investigative Site Fullerton, California, United States
  • Novartis Investigative Site Sacramento, California, United States
View all 166 locations
View Trial Details
Completed

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

NCT01628393

Conditions
Relapsing Multiple Sclerosis
Locations
  • Alta Bates Summit Medical Center Berkeley, California, United States
  • Neuro Pain Medical Center Fresno, California, United States
  • University of California Davis Medical Center Sacramento, California, United States
  • The Neurological Institute PA Charlotte, North Carolina, United States
View all 58 locations
View Trial Details

Related conditions